Story

Shattuck Labs Stock Slides as Wider Loss Overshadows Pipeline Progress

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Shattuck Labs Stock Slides as Wider Loss Overshadows Pipeline Progress
Text size
Background

Shattuck Labs (NASDAQ: STTK) shares declined in pre-market trading after the company released second-quarter 2026 financial results that showed a wider net loss and higher research costs, overshadowing positive clinical trial developments.

Financial Performance

The clinical-stage biotechnology firm reported a net loss of $15.2 million for the second quarter, an increase from the $12.5 million net loss recorded in the same period a year ago. According to the earnings report, the wider loss was driven by a significant rise in operating expenses.

Research and development (R&D) expenses climbed 34% year-over-year to $11.7 million, a figure that surpassed analyst expectations. As a pre-revenue company, Shattuck Labs did not report any income for the quarter.

Pipeline and Clinical Updates

Despite the weaker financial metrics, Shattuck Labs provided a constructive update on its drug pipeline. The company announced positive Phase 1 data for its lead candidate, SL-325, an antibody targeting the TL1A pathway. The results indicated a favorable safety profile and durable receptor blockade for more than three months at therapeutic doses.

Sample IUX Markets – In-articleAd

CEO Taylor Schreiber stated that the Phase 1 data "checked all of the boxes," positioning SL-325 competitively for further studies. The company confirmed its Phase 2b trial in Crohn’s disease patients is on track to begin in the current quarter. Shattuck also introduced a new candidate, SL-846, with initial data anticipated in 2027.

Market Context

The stock's decline reflects a common dynamic for development-stage biotech firms, where higher-than-expected spending can weigh on sentiment even amid clinical progress. The pullback also occurred as the stock was trading near its 52-week high, making it susceptible to profit-taking on a mixed report.

However, the company's financial position remains robust. Shattuck Labs ended the quarter with approximately $208.3 million in cash and investments, which it stated provides an operational runway into 2029. This strong balance sheet may provide a floor for the stock as investors assess the long-term potential of its pipeline.

Read next

More on Stocks
Back to latest news

LATEST